4 months ago
DFTX
AnalystsPaul MatteisPaul Matteis's Stock Forecasts
AnalystsPaul Matteis
Analyst Ranking
Bottom 20%
#4472 out of 5557 analysts
Average Return
-0.11%
Win Rate
41%43 out of 104
Risk vs Reward
Poor
Good
Paul Matteis's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Alto Neuroscience IncANRO | +213.47% | $4.53 | $14.20 | 2024-11-13 - 2025-11-12 | Strong Buy |
Dyne Therapeutics IncDYN | +161.22% | $9.85 | $25.73 | 2025-07-31 - 2026-07-30 | Strong Buy |
Sionna Therapeutics IncSION | +130.34% | $14.80 | $34.09 | 2025-03-04 - 2026-03-03 | Strong Buy |
Lb Pharmaceuticals IncLBRX | +128.67% | $15.14 | $34.62 | 2025-10-06 - 2026-10-05 | Strong Buy |
Lb Pharmaceuticals IncLBRX | +122.15% | $20.23 | $44.94 | 2025-12-11 - 2026-11-10 | Strong Buy |
Paul Matteis Analyst Color
Get additional color on Paul Matteis's coverage of popular stocks
4 months ago
CMPS
a year ago
NBIX
a year ago
BMRN
Paul Matteis's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
City Therapeutics IncCTY | 1 | Strong Buy | $34.00 | +73.29% | Initiates Coverage On | a day ago |
Mentari Therapeutics IncMTRI | 1 | Strong Buy | $30.00 | +145.90% | Initiates Coverage On | a day ago |
Vertex Pharmaceuticals IncVRTX | 17 | Hold | $563.00 | +2.76% | Maintains | 8 days ago |
Biomarin Pharmaceutical IncBMRN | 12 | Hold | $66.00 | +15.53% | Maintains | 8 days ago |
Korsana Biosciences IncKRSA | 1 | Strong Buy | $43.00 | +38.22% | Initiates Coverage On | 2 months ago |
Neurocrine Biosciences IncNBIX | 9 | Strong Buy | $215.00 | +27.11% | Maintains | 3 months ago |
Alnylam Pharmaceuticals IncALNY | 11 | Strong Buy | $318.00 | +109.71% | Maintains | 3 months ago |
Acadia Pharmaceuticals IncACAD | 8 | Hold | $25.00 | +36.76% | Maintains | 4 months ago |
Alkermes PLCALKS | 6 | Strong Buy | $63.00 | +35.57% | Reiterates | 4 months ago |
Definium Therapeutics IncDFTX | 2 | Strong Buy | $60.00 | +73.21% | Maintains | 4 months ago |
Compass Pathways PLCCMPS | 2 | Strong Buy | $21.00 | +127.03% | Maintains | 4 months ago |
Maplight Therapeutics IncMPLT | 2 | Strong Buy | $36.00 | +383.87% | Maintains | 5 months ago |
Seaport Therapeutics IncSPTX | 1 | Strong Buy | $30.00 | +36.55% | Initiates Coverage On | 6 months ago |
Sionna Therapeutics IncSION | 2 | Strong Buy | $55.00 | +1,386.49% | Maintains | 6 months ago |
Immunic IncIMUX | 1 | Strong Buy | $25.00 | +210.95% | Initiates Coverage On | 7 months ago |
Lb Pharmaceuticals IncLBRX | 3 | Strong Buy | $40.00 | -10.99% | Maintains | 7 months ago |
Denali Therapeutics IncDNLI | 4 | Strong Buy | $41.00 | +106.55% | Maintains | 8 months ago |
Kalvista Pharmaceuticals IncKALV | 2 | Strong Buy | $42.00 | +55.56% | Maintains | 8 months ago |
Ionis Pharmaceuticals IncIONS | 6 | Hold | N/A | N/A | Maintains | 9 months ago |
Uniqure NvQURE | 3 | Strong Buy | $40.00 | +76.13% | Maintains | a year ago |
Dyne Therapeutics IncDYN | 5 | Strong Buy | $39.00 | +117.63% | Maintains | a year ago |
Neumora Therapeutics IncNMRA | 3 | Hold | $3.00 | +542.40% | Maintains | a year ago |
Biogen IncBIIB | 7 | Strong Buy | $202.00 | N/A | Upgrades | a year ago |
Pepgen IncPEPG | 3 | Strong Buy | $12.00 | N/A | Maintains | a year ago |
Rhythm Pharmaceuticals IncRYTM | 2 | Strong Buy | $94.00 | N/A | Maintains | a year ago |
Vigil Neuroscience IncVIGL | 2 | Hold | $8.00 | N/A | Downgrades | a year ago |
Gh Research PLCGHRS | 2 | Strong Buy | $32.00 | N/A | Maintains | 2 years ago |
Sage Therapeutics IncSAGE | 5 | Hold | $6.00 | N/A | Maintains | 2 years ago |
Alector IncALEC | 5 | Hold | $4.00 | N/A | Downgrades | 2 years ago |
Alto Neuroscience IncANRO | 3 | Strong Buy | $10.00 | N/A | Maintains | 2 years ago |
Neurogene IncNGNE | 2 | Strong Buy | $60.00 | N/A | Maintains | 2 years ago |
Rapport Therapeutics IncRAPP | 1 | Strong Buy | $35.00 | N/A | Initiates Coverage On | 2 years ago |
Contineum Therapeutics IncCTNM | 1 | Strong Buy | $29.00 | N/A | Initiates Coverage On | 3 years ago |
Lexeo Therapeutics IncLXEO | 1 | Strong Buy | $20.00 | N/A | Initiates Coverage On | 3 years ago |
Vistagen Therapeutics IncVTGN | 1 | Strong Buy | $12.00 | N/A | Initiates Coverage On | 3 years ago |
Karuna Therapeutics IncKRTX | 3 | Strong Buy | $295.00 | N/A | Maintains | 4 years ago |
Cerevel Therapeutics Holdings IncCERE | 2 | Strong Buy | $54.00 | N/A | Maintains | 4 years ago |
Leonabio IncLONA | 2 | Hold | $50.00 | N/A | Downgrades | 4 years ago |
Climb Bio IncCLYM | 1 | Strong Buy | $35.00 | N/A | Initiates Coverage On | 5 years ago |
Acumen Pharmaceuticals IncABOS | 1 | Strong Buy | $27.00 | N/A | Initiates Coverage On | 5 years ago |
Prevail Therapeutics IncPRVL | 1 | Strong Buy | $23.00 | N/A | Initiates Coverage On | 6 years ago |
Gw Pharmaceuticals PLCGWPH | 4 | Hold | $140.00 | N/A | Downgrades | 6 years ago |
Avadel Pharmaceuticals PLCAVDL | 1 | Strong Buy | $14.00 | N/A | Initiates Coverage On | 7 years ago |
Zogenix IncZGNX | 3 | Buy | $60.00 | N/A | Initiates Coverage On | 8 years ago |
Acorda Therapeutics IncACORQ | 1 | Hold | $2,280.00 | N/A | Maintains | 8 years ago |
Akcea Therapeutics IncAKCA | 2 | Hold | $31.00 | N/A | Maintains | 8 years ago |
Obseva SaOBSVF | 1 | Buy | $18.00 | N/A | Maintains | 9 years ago |
Wave Life Sciences IncWVE | 1 | Buy | $64.00 | N/A | Maintains | 9 years ago |
Cidara Therapeutics IncCDTX | 1 | Buy | $340.00 | N/A | Initiates Coverage On | 10 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.